2022 World Conference on Lung Cancer (ePosters)-EP08.01-077. Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC

EP08.01-077. Predicting Response to Checkpoint Inhibitors Using Complex Molecular Characteristics and Immunoprofiling in Patients With NSCLC

Back to course

Pdf Summary

Researchers in the Czech Republic have conducted a study to predict the response to checkpoint inhibitors in solid tumors using molecular characteristics and immunoprofiling. The study included 80 patients with advanced or metastatic solid tumors who were treated with anti-PD-1/PD-L1 antibodies. The researchers evaluated different immune cell populations and markers in tumor tissue using immunohistochemistry. They also performed DNA analysis to assess tumor mutational burden and analyzed peripheral blood for immune regulators and effectors using flow cytometry. In addition, the researchers used mass spectrometry to identify probable neoantigens. The study focused on patients with non-small cell lung cancer (NSCLC) and found that nuclear FOXP3 negativity was associated with prolonged progression-free survival and overall survival in this group. However, there were no other statistically significant differences between overall survival and tumor subpopulations of immune cells or markers. The researchers concluded that there cannot be a single biomarker for immunotherapy response and further confirmation is needed due to the small and heterogeneous study population. Overall, this study highlights the importance of evaluating complex molecular characteristics and immunoprofiling in predicting the response to checkpoint inhibitors in solid tumors.

Asset Subtitle

Simona Borilova

Meta Tag

Speaker Simona Borilova

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Czech Republic

study

predict

checkpoint inhibitors

solid tumors

molecular characteristics

immunoprofiling

anti-PD-1/PD-L1 antibodies

tumor mutational burden

nuclear FOXP3 negativity